Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

Journal for immunotherapy of cancer·2026
Same author

Editor's Note: Inhibition of NF-κB-Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma.

Cancer research·2026
Same author

Skin health in oncology: evidence-based skin care for cancer patients.

The oncologist·2026
Same author

Female sex is associated with worse survival in laryngeal head and neck squamous cell carcinoma.

The oncologist·2026
Same author

Pharmacists are responsible for patient outcomes when dispensing opioids.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2026
Same author

Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial Update.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Related Experiment Video

Updated: Oct 6, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.6K

Clinical Utilization, Utility, and Reimbursement for Expanded Genomic Panel Testing in Adult Oncology.

Susan J Hsiao1, Anthony N Sireci1, Danielle Pendrick1

  • 1Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY.

JCO Precision Oncology
|January 20, 2022
PubMed
Summary

Next-generation sequencing (NGS) pan-cancer panels identify actionable alterations in 64% of high-risk cancer patients. However, limited insurance coverage and low reimbursement hinder widespread clinical adoption of this vital genomic testing.

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.0K

Related Experiment Videos

Last Updated: Oct 6, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.6K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.0K

Area of Science:

  • Genomic Medicine
  • Oncology
  • Molecular Diagnostics

Background:

  • Next-generation sequencing (NGS) pan-cancer panels are crucial for identifying rare, actionable genetic alterations to guide cancer therapy.
  • Clinical adoption of NGS testing is impeded by inconsistent insurance coverage and variable reimbursement policies.
  • This study reviews the utilization, clinical utility, coverage, and reimbursement of a comprehensive NGS pan-cancer panel in high-risk cancer patients.

Purpose of the Study:

  • To evaluate the clinical utility and economic viability of a large-gene next-generation sequencing (NGS) pan-cancer panel in a real-world clinical setting.
  • To assess test utilization patterns, identify clinically impactful findings, and analyze coverage and reimbursement rates for NGS testing in high-risk cancer patients.

Main Methods:

  • The Columbia Combined Cancer Panel (CCCP), a 467-gene NGS panel, was performed on 359 high-risk tumors from 349 patients.
  • Test utilization was tracked, and clinical utility was determined by a multidisciplinary molecular tumor board.
  • Reimbursement data were analyzed following final payer coverage decisions.

Main Results:

  • Clinically impactful alterations were identified in 64% of cases, with 42% revealing alterations for potential future therapy.
  • Targeted therapy was initiated in 6.6% of patients.
  • A significant majority of tests (77%) were denied coverage by payers, with an average reimbursement of only 10.75% of the service charge.

Conclusions:

  • The CCCP identified clinically significant genomic alterations in a majority of high-risk cancer patients, demonstrating its utility.
  • Limited insurance coverage and inadequate reimbursement represent substantial barriers to the routine clinical implementation of pan-cancer NGS panels.
  • Broader reimbursement policies are essential to facilitate the adoption of beneficial NGS testing for improved patient care.